ArticleAnnals of surgical oncology2026
Imaging Overestimates the Local Extent of Breast Tumor After Neoadjuvant Chemotherapy.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current study was performed to analyze the accuracy of imaging in determining the amount of residual tumor after neoadjuvant chemotherapy. The hypothesis was that imaging overestimated the local extent of tumor in breast in a significant proportion of patients, contributing to the selection of mastectomy as the definitive surgical procedure. PATIENTS AND
methodsA retrospective analysis was performed for patients with newly diagnosed invasive breast cancer treated with NAC from 2015 through 2023. Imaging characteristics after NAC were compared with tumor size on final pathology. Imaging overestimation and underestimation were defined as size on imaging > 1 cm either greater than or less than the final size on pathology, respectively.
resultsOf 274 patients receiving NAC, there were 21(17%) patients who had false-positive and 24(28%) with false-negative imaging post-NAC. There were 181 patients who did not have radiographic complete response post-NAC, for whom mean radiographic tumor size post-NAC was 3.2 cm. Comparison of T size on post-NAC imaging versus final pathology yielded a correlation coefficient of 0.579. Radiographic assessment overestimated final pathology tumor size by > 1 cm in 81 (45%) of 181 patients overall. Rates of overestimation were not associated with tumor biomarker status or multi-focality/centricity but were significantly higher on post-NAC imaging for ycT2 (55%, p < 0.001) and ycT3 (67%, p < 0.001) versus ycT1 (25%, Ref.) tumors.
conclusionsThese results cast uncertainty on the reliability of post-NAC imaging to guide selection of the breast surgical procedure, especially when there is ycT3 tumor remaining after neoadjuvant systemic therapy.
Indexed as
Identifiers
42401721What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.